Precision Theranostics for Triple Negative Breast Cancer Using Transformed MUC1 Targeting

A promising Indium-111/Actinium-225 antibody pair shows dramatic tumor regression in aggressive breast cancer

Triple negative breast cancer (TNBC) represents one of oncology’s most challenging frontiers—aggressive, difficult to treat, and lacking targeted therapy options. This comprehensive preclinical study presents compelling evidence for a novel theranostic approach that could change treatment paradigms for the 90% of TNBC patients whose tumors express transformed MUC1 (tMUC1).

The research demonstrates how humanized antibody hTAB004, when radiolabeled with Indium-111 for imaging and Actinium-225 for alpha-particle therapy, achieves remarkable tumor targeting (65% injected dose per gram at 120 hours) while maintaining favorable safety profiles. A single therapeutic dose produced significant tumor shrinkage and substantially extended survival in orthotopic mouse models, establishing proof-of-concept for this precision medicine approach.

Why Read this Publication:

• Addresses unmet need: Explore a targeted solution for TNBC, which affects 15% of breast cancer patients but has limited treatment options beyond chemotherapy
• Complete theranostic workflow: See the full development pipeline from antibody humanization through radiolabeling, imaging, dosimetry, and therapeutic efficacy
• Alpha-particle therapy: Understand the advantages of Actinium-225’s potent, highly localized cell-killing combined with antibody-mediated internalization
• Clinical translation pathway: Review human dosimetry calculations showing comparable safety profiles to established radiopharmaceuticals, supporting clinical development
• Dramatic efficacy results: Examine data showing 90% tumor volume reduction and significantly extended survival from a single treatment dose

Learn more about Perceptive Discovery’s preclinical oncology services here